ロード中...
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
INTRODUCTION: Clinical trials conducted in patients with type 2 diabetes (T2DM) treated with glucose-lowering drugs and examining cardiovascular-related outcomes have yielded mixed results. In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagl...
保存先:
| 出版年: | Diabetes Ther |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6064600/ https://ncbi.nlm.nih.gov/pubmed/29949014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0456-7 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|